Skip to main content

Column Group LLC

13F filer · CIK 0001833486
Reported Aug 14, 2026
13F portfolio value$88.1MU.S. long equity reported on 13F
Positions30 new · 0 closed
Net flow last quarter$0Buys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 20263 positions
SRZNSurrozen, Inc.$49.7M56.46%16.31%Not reportedQ3 2021
ORICOric Pharmaceuticals, Inc.$38.3M43.53%3.42%Not reportedQ4 2020
RVMDRevolution Medicines, Inc.$8.62K0.01%0.00%Not reportedQ4 2020
Q1 2026Reported May 18, 20263 positions
SRZNSurrozen, Inc.$55.8M55.45%16.68%+3.5%Q3 2021
ORICOric Pharmaceuticals, Inc.$44.9M44.55%3.42%Not reportedQ4 2020
RVMDRevolution Medicines, Inc.$4.47K0.00%0.00%Not reportedQ4 2020
Q4 2025Reported Feb 13, 20265 positions
SRZNSurrozen, Inc.$41.8M50.54%18.94%+23.4%Q3 2021
ORICOric Pharmaceuticals, Inc.$29M34.98%3.59%Not reportedQ4 2020
TNYATenaya Therapeutics, Inc.$6.69M8.08%4.34%Not reportedQ3 2021
RAPTRAPT Therapeutics, Inc.$5.29M6.39%0.56%-5.9%Q4 2020
RVMDRevolution Medicines, Inc.$3.66K0.00%0.00%Not reportedQ4 2020
Q3 2025Reported Nov 14, 20255 positions
ORICOric Pharmaceuticals, Inc.$42.5M52.48%3.64%Not reportedQ4 2020
SRZNSurrozen, Inc.$19.3M23.88%17.50%Not reportedQ3 2021
TNYATenaya Therapeutics, Inc.$14.9M18.35%5.77%Not reportedQ3 2021
RAPTRAPT Therapeutics, Inc.$4.28M5.29%1.00%-87.5%Q4 2020
RVMDRevolution Medicines, Inc.$2.15K0.00%0.00%Not reportedQ4 2020
Premium opens every quarter this fund has filed
SpoorBase

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.